Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study

Cohort study (38 patients with creatinine clearance <30ml/min not on dialysis) found that all patients given ledipasvir 90 mg with sofosbuvir 400 mg achieved sustained virological response 12 weeks after treatment. Adverse events were mostly mild or moderate.